Cargando…
Hormonal Modulation of ESR1 Mutant Metastasis
Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer (MBC), and confer clinical resistance to aromatase inhibitors (AIs). Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migratio...
Autores principales: | Gu, Guowei, Tian, Lin, Herzog, Sarah K., Rechoum, Yassine, Gelsomino, Luca, Gao, Meng, Du, Lili, Kim, Jin-Ah, Dustin, Derek, Lo, Hin Ching, Beyer, Amanda R., Edwards, David G., Gonzalez, Thomas, Tsimelzon, Anna, Huang, Helen J., Fernandez, Natalie M., Grimm, Sandra L., Hilsenbeck, Susan G., Liu, Dan, Xu, Jun, Alaniz, Alyssa, Li, Shunqiang, Mills, Gordon B., Janku, Filip, Kittler, Ralf, Zhang, Xiang H.-F., Coarfa, Cristian, Foulds, Charles E., Symmans, W. Fraser., Andò, Sebastiano, Fuqua, Suzanne A.W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020875/ https://www.ncbi.nlm.nih.gov/pubmed/33323970 http://dx.doi.org/10.1038/s41388-020-01563-x |
Ejemplares similares
-
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
por: Dustin, Derek, et al.
Publicado: (2020) -
Phosphorylation of the Mutant K303R Estrogen Receptor α at Serine 305 Impacts Aromatase Inhibitor Sensitivity
por: Barone, Ines, et al.
Publicado: (2010) -
The promise of microarrays in the management and treatment of breast cancer
por: Chang, Jenny C, et al.
Publicado: (2005) -
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2023) -
Genomic approaches in the management and treatment of breast cancer
por: Chang, J C, et al.
Publicado: (2005)